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Abstract The category of IFG was introduced in the late
1990s to denote a state of non-diabetic hyperglycaemia
defined by a fasting plasma glucose (FPG) concentration
between 6.1 and 6.9 mmol/l. In 2003 the American
Diabetes Association recommended that this diagnostic
threshold be lowered to 5.6 mmol/l. The justification for
lowering the threshold has been questioned. This simple
change in cut-off value creates a pandemic of IFG, with a
two- to five-fold increase in the prevalence of IFG across
the world. Such a change in threshold has far-reaching
public health implications. The European Diabetes Epide-
miology Group (EDEG) has reviewed the evidence for this
lower cut-off point for the definition of IFG and concludes
that the previous definition should not be altered. EDEG
further recommends that the value of all categorical
definitions of non-diabetic hyperglycaemia should be
reconsidered.
Abbreviations ADA: American Diabetes Association .
CVD: cardiovascular disease . DECODE: diabetes
epidemiology collaborative analysis of diagnostic criteria
in Europe . DESIR: data from an epidemiological study on
the insulin resistance syndrome . EDEG: European
Diabetes Epidemiology Group . FPG: fasting plasma
glucose . HR: hazard ratio . IFG: impaired fasting glucose .
RR: relative risk
Introduction
The category of IFG was first introduced in the revision of
the diagnostic criteria for diabetes when the American
Diabetes Association (ADA) in 1997, and theWorld Health
Organization in 1999 recommended that a fasting plasma
glucose (FPG) value of ≥6.1 and <7.0 mmol/l (≥110 and <
126 mg/dl) should be used to define this state. The main
reason was to create a fasting category which would be
analogous to IGT defined according to the 75-g post-load
glucose levels. In 2003, the ADA recommended that the
threshold for diagnosing IFG should be lowered to
5.6 mmol/l or 100 mg/dl [1]. This was justified by the
desire to identify similar proportions of the population with
IFG and IGT, and to produce equivalent predictive power
for progression to diabetes from the IGT and IFG
categories.
This recommendation has been re-endorsed in subse-
quent ADA position statements. However, acceptance of
the new criteria has not been universal. At its 2005 Annual
Meeting, the European Diabetes Epidemiology Group
(EDEG), a subgroup of the European Association for the
Study of Diabetes, resolved to review the evidence for
lowering the threshold for IFG from 6.1 mmol/l to
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5.6 mmol/l and to make recommendations for use in
Europe. This paper summarises this evidence and presents
the EDEG recommendations for the threshold for defining
IFG.
The relationship between levels of fasting glucose
and future risk of diabetes
A considerable amount of attention in the literature has
been paid to comparisons between IFG and IGT and the
relative merits of one compared with the other in predicting
future diabetes [2, 3]. However, in the context of
considering the threshold for defining IFG, these compar-
ison arguments are less clinically relevant because usually
in clinical practice risk prediction will occur using only the
fasting level without knowledge of the 2 h value. Thus,
what is important is the shape of the risk curve relating
levels of fasting glucose to the future risk of incident
diabetes.
We examined the magnitude of the association between
different thresholds for IFG and diabetes from published
data, or derived it from the published data when it was not
available directly (Table 1). Overall, the magnitude of the
association between diabetes and IFG is greater for IFG
defined as FPG 6.1–6.9 mmol/l than for the new category
of FPG 5.6–6.0 mmol/l. The Data from an Epidemiological
Study on the Insulin Resistance Syndrome (DESIR) study
in France demonstrated this trend in both men and women:
diabetes incidence rates per 1,000 person-years for IFG
categories of <5.6, 5.6–6.0 and 6.1–6.9 mmol/l were,
respectively, 1.8, 5.7, and 43.2 in men and 0.7, 6.2 and 54.7
in women [4]. Thus, the incidence rate of diabetes in the
new IFG group was less than one-seventh of that of the
original IFG group. A recent study from rural Italy supports
these findings. In a population-based prospective study of
1,441 Italian adults (the Brisighella Heart Study), at 8 years
of follow-up, IFG (FPG 6.1–6.9 mmol/l) was significantly
associated with incident diabetes, but basal glycaemia
under 6.1 mmol/l was not significantly associated with
future diabetes [5]. We found no published evidence that
the new lower IFG cut-off point confers any benefit in the
identification of future diabetes that is not already
identified by the original cut-off point of 6.1 mmol/l. Of
course, a lowering of the threshold will improve the
sensitivity of IFG as a predictor of diabetes but at the cost
of specificity. As we argue later in this paper, deciding
where to draw the line is not straightforward. So, what do
we know about the shape of the risk curve relating fasting
glucose to new-onset diabetes? In a study of 4,721 non-
diabetic individuals with a repeat OGTT at 5 years of
follow-up, the risk of incident diabetes increased with
increasing baseline fasting glucose, but there was little
evidence of a threshold effect near 6.1 mmol/l [6]. A
threshold effect, however, is reported in Pima Indians, in
whom the risk of diabetes increased gradually over most of
the distribution of fasting glucose values, but the incidence
rate increased markedly at fasting glucose concentrations
above ∼100 mg/dl (5.6 mmol/l) [7]. It may be that only
some populations demonstrate a risk threshold. For
European populations there is no evidence of such a
threshold. Indeed, recent evidence suggests that higher
fasting glucose levels within the normoglycaemic range
constitute an independent risk factor for type 2 diabetes
among young men [8]. In the large Israeli prospective study
of 13,163 healthy men with fasting glucose concentrations
Table 1 Association of incident diabetes with impaired fasting glucose defined by different cut-off points
Study Population Reference
category
RR (95% CI) for incident diabetes
IFG category 6.1 to <7.0 mmol/l
RR (95% CI) for incident diabetes new
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lower than 5.6 mmol/l at baseline, the 6-year risk of
incident diabetes increased progressively with FPG con-
centrations of 4.83 mmol/l or more compared with those in
the bottom quintile (FPG<4.5 mmol/l) [8].
On the basis of this evidence, it appears that fasting
plasma glucose levels represent a continuum of risk for
diabetes. Consequently, the choice of a level of fasting
glucose to categorise people into groups based on the
future risk of diabetes is somewhat arbitrary since the
population does not divide neatly into those with and
without risk. Even if risk were to be dichotomous,
progression to diabetes should not be the only foundation
on which risk strata are based. The public health
consequences of diabetes are mostly related to cardiovas-
cular complications and thus it is important to study how
non-diabetic hyperglycaemia is associated not just with
progression to diabetes but also with cardiovascular
incidence and mortality.
Relationship between raised levels of fasting glucose
and future risk of cardiovascular disease or death
A continuum of cardiovascular disease (CVD) risk and
both total and CVD mortality with increasing post-
challenge glucose has been shown consistently in multiple
studies, but the association of this risk with fasting glucose
has been less well defined. The Diabetes Epidemiology
Collaborative Analysis Of Diagnostic Criteria in Europe
(DECODE) study among 22 European cohorts (and nearly
30,000 participants) reported that there was no glycaemic
threshold for either fasting or 2 h glucose above which total
mortality increased sharply [9]. Both very low and high
fasting glucose levels were associated with total and CVD
death in a J-shaped relationship, but for 2 h glucose and
CVD mortality there was a graded association [9]. A recent
study among 23,755 men in Taiwan found that, consistent
with the DECODE findings, there was a J-shaped associ-
ation between all-cause mortality and fasting blood glucose
[10]. Recent data on 237,468 individuals in the Asia-
Pacific Cohort Collaboration found that there was a
positive log-linear association between usual fasting glu-
cose (i.e. fasting glucose corrected for regression dilution
bias) and the risk of total stroke and ischaemic heart disease
events. The association was continuous down to a glucose
level of 4.9 mmol/l, without a threshold effect [11]. A
recent meta-analysis of 38 prospective studies reported that
the post-challenge blood glucose level in the non-diabetic
range had a linear relationship with CVD risk. However,
the association with fasting glucose was non-linear, with a
possible threshold effect at around 5.6 mmol/l [12]. A
caveat is that the studies included in the meta-analysis were
very heterogeneous: different CVD end-points were mea-
sured; glucose levels were based on highest and lowest
categories which were not uniform across studies; and
although CVD risk factors were adjusted for, history of
previous CVD was not explicitly adjusted for in the
analyses.
Further evidence against lowering the threshold of IFG
definition comes from a Taiwanese study [10]. IFG, when
defined as 6.1–6.9 mmol/l, was associated with a signif-
icant increase in CVD and/or diabetes mortality (the
relative risk [RR] ranging between 1.3 and 7.0). However,
when IFG was defined as 5.6–6.9 mmol/l, the predictive
value of IFG was abolished and the mortality risks were
diminished substantially because of the inclusion of the
5.6–6.1 mmol/l group, in which the RR ranged non-
significantly between 0.9 and 2.5 [10]. The findings were
replicated for total mortality in the Baltimore Longitudinal
Study of Aging [13]. Among 1,236 men followed for
13 years, the risk of mortality did not increase until the FPG
exceeded 6.1 mmol/l. The RR for mortality was 1.03 (95%
CI 0.80–1.32) in the FPG group 5.6–6.1 mmol/l, whereas
the risk was elevated by 40% in the FPG group 6.1–
6.9 mmol/l (RR 1.41, 1.01–1.97), the authors finding no
support for the lowering of IFG to 5.6 mmol/l from
6.1 mmol/l for the outcome of mortality [13]. Nearly
identical findings were reported from the Dutch Hoorn
study, in which the age- and sex-adjusted RR for CVD
mortality was 1.43 (0.79–2.60) in the FPG group 6.1–
6.9 mmol/l, but 0.63 (0.34–1.19) in the new IFG group of
5.6–6.0 mmol/l [14]. For the outcome of incident CVD
events, the only data comparing IFG thresholds come from
a prospective study of secondary prevention in women with
established coronary heart disease (CHD) [15]. They
reported that women with IFG according to the 1997
ADA definition (FPG 6.1–6.9 mmol/l) had an increased
risk of any CHD event (hazard ratio [HR] 1.37, 95% CI
1.08–1.74), but those with the modified 2003 ADA
definition (FPG 5.6–6.9 mmol/l) were not at increased
risk (HR 1.09, 0.90–1.34), nor were women in the fasting
glucose range of 5.6–6.0 mmol/l (HR 0.90, 0.73–1.12)
[15], further undermining the appropriateness of the
lowering of the IFG threshold.
Although there are few studies relating non-diabetic
hyperglycaemic categories to CVD outcomes, IGT, but not
IFG, has consistently been associated with CHD risk
factors. The Risk factors in IGT for Atherosclerosis and
Diabetes (RIAD) study reported that the intima-media
thickness (IMT) of the common carotid artery (as a marker
of atherosclerosis) in individuals with isolated IFG did not
differ from that in controls with NGT, but that the IMTwas
greater in those with isolated IGT and combined IFG and
IGT [16]. They also found that an FPG below 7.0 mmol/l
was not related to IMT, but post-challenge glucose was
predictive of IMT in individuals with IFG (6.1–7.0 mmol/l)
and in those with normoglycaemia (FPG<6.1 mmol/l) [17].
Both the Baltimore Longitudinal Study on Aging [18] and
an Italian study [19] reported a higher prevalence of CHD
risk factors among those with IGT but not among those
with IFG alone, when compared with normoglycaemic
individuals. This was the case whether the original (FPG
6.1–6.9 mmol/l) or the modified (FPG 5.6–6.9 mmol/l)
definition of IFG was used [18, 19].
In summary, existing evidence suggests that no benefit
will be gained by lowering the IFG threshold in the context
of risk association with CVD or mortality.
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Evidence that reduction in fasting glucose levels lowers the
risk of diabetes or cardiovascular disease
There is convincing evidence from primary prevention
clinical trials that lifestyle interventions, including weight
loss and increased physical activity, or drug therapy with
metformin or acarbose are effective in delaying the onset of
diabetes in people with IGT [20–23]. There is also
emerging evidence for the possible primary prevention of
CVD among those with IGT. The multicentre STOP-
NIDDM (Study to prevent non-insulin-dependent diabetes
mellitus) study reported a 49% relative risk reduction (and
2.5% absolute risk reduction) for cardiovascular events
with acarbose treatment in those with IGT [24]. In contrast,
a recent report of the US Diabetes Prevention Program
(DPP) did not replicate this finding for metformin, but there
was a risk reduction in hypertension with intensive lifestyle
intervention [25].
There are no similar data for the effectiveness of lifestyle
or drug interventions in individuals with IFG. The only
published data are from the Fasting Hyperglycaemia Study,
in which 227 self-referred non-diabetic individuals with
raised plasma glucose (5.5–7.7 mmol/l) were evaluated
[26, 27]. Reinforced healthy lifestyle advice did not
achieve sustained lifestyle changes, as measured by body
weight and did not result in reduction in glycaemia at the 1-
year follow-up when compared with a programme of basic
healthy lifestyle advice [26]. Sulfonylurea therapy im-
proved glycaemic control and beta cell function at 1 year,
but progression to diabetes was not measured [27].
Currently, therefore, there is no evidence of the primary
prevention of diabetes or CVD among those with IFG.
The benefits and harm of labelling individuals
with raised fasting glucose
There is no published evidence that labelling individuals
with IFG will provide clinical or public health benefits.
One might speculate that those who are labelled with the
diagnosis of IFG might adopt healthy lifestyle advice, but
there are no data demonstrating benefit in people with
fasting plasma glucose of 5.6–6.9 mmol/l (100–126 mg/dl)
who do not also have IGT. There might be potential harm in
labelling people; for example, life or medical insurance
premiums could potentially increase and IFG could be
considered as a pre-existing condition, and thus costs
incurred for subsequent diabetes may not be paid [28].
In general, those who have IFG (whether in the range of
6.1–6.9 mmol/l or 5.6–6.0 mmol/l) concurrently have
several features of the metabolic syndrome, such as
dyslipidaemia, hypertension and central obesity. The direct
clinical management of these conditions may be necessary,
but is not dependent upon labelling a person as having IFG.
The scale of the rise in prevalence of IFG
with the proposed change in diagnostic threshold
It is a truism that when a diagnostic threshold is lowered,
more people will be classified as having that condition.
Extrapolating from the National Health and Nutrition
Examination Survey (NHANES) data, the prevalence of
IFG in the US population would increase from 6.7% (∼12
million people) to 24.1% (∼44 million people) with the
lower threshold, particularly among the 20- to 50-year-olds
(a greater than fivefold increase from 3.1 to 17.3%) [28].
The lowered threshold would increase the prevalence of
IFG from 11.8 to 37.6% in Denmark, from 15.9 to 45.2% in
France, from 11.2 to 26.7% in urban China, from 10.6 to
37.6% in urban India, from 9.5 to 28.5% in the USA [29]
and from 9.5 to 32.3% in Singapore [30]. Thus, lowering
the threshold for diagnosis of IFG increases the prevalence
of IFG two to fivefold in most populations. The
implications of this two to fivefold increase in prevalence
are not known. To our knowledge, no modelling has been
undertaken to assess the public health impact of the
increase in prevalence of IFG that would follow a lowering
of the diagnostic cut-off point for IFG.
The rationale for the lower cut-off point for IFG
In the ADA 2003 follow-up report the Expert Committee
stated that the rationale for lowering the cut-off point from
110 to 100 mg/dl (6.1–5.6 mmol/l) was based on
examining the receiver operating characteristic (ROC)
curve of the ability of various baseline levels of FPG to
predict diabetes. They reported that the FPG value at the
point on the ROC curve closest to the ideal of 100%
sensitivity and 100% specificity over the glycaemic range
of 81–126 mg/dl (4.5–7.0 mmol/l) was 103 mg/dl
(5.7 mmol/l) in a Dutch population, 97 mg/dl (5.4 mmol/
l) in a Pima Indian group, 94 mg/dl (5.2 mmol/l) in a
Mauritius population and 94 mg/dl (5.2 mmol/l) in a San
Antonio population. Based on this, the Expert Committee
recommended that changing the cut-off point to 100 mg/dl
(5.6 mmol/l) would optimise its sensitivity and specificity
for predicting future diabetes. This analysis assumes that
all populations show the same relationship between fasting
glucose and diabetes incidence, which we have argued may
not be the case. It also assumes that optimising both
sensitivity and specificity is the desirable strategy. The
decision about where to draw any cut-off point on a
continuous scale relates to the relative harm from being a
false positive compared with a false negative. This in turn
is dependent upon the treatment consequences that follow
from attribution of a label. One cannot divorce the issue of
cut-off point evaluation from the evidence of efficacy of
intervention for those who fall above the line. At a time
when there is no evidence of long-term benefit, the balance
must lie with maximising specificity, and this argues for
leaving the threshold unaltered.
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Summary and recommendations
Identifying and labelling those at higher risk of diabetes
does not necessarily ensure that their health will be
improved. Currently there is no convincing evidence that
the attribution of the label of IFG, even without a change in
its diagnostic threshold, will achieve better health
outcomes.
The ADA Expert Committee on the Diagnosis and
Classification of Diabetes acknowledge that ‘the factors
that should influence the choice of the cut point are not
currently known for IFG. For example, we do not yet know
the total benefit or the total cost to an individual who is
designated at risk for diabetes by either test, by any
criterion’ [1]. In our view it is not logical to lower the
threshold for diagnosis and create a pandemic of IFG,
without serious consideration of its impact on the
individual or the health-care system.
Throughout this paper we have referred to raised glucose
in people without diabetes as ‘non-diabetic hyperglycae-
mia’. We believe this descriptive term is preferable to
others in use, such as ‘dysglycaemia’ and ‘impaired fasting
glucose’, which are misnomers. We would also suggest
avoidance of the term ‘pre-diabetes’ since this implies that
if one has IFG or IGT, then one is in a state that will
definitely progress to diabetes, which is not the case. Many
people revert to normoglycaemia on subsequent testing
after a first test showing raised glucose levels, and there is
no fixed state of pre-diabetes.
EDEG recommends that we retain the originally
suggested diagnostic cut-off point for IFG at 6.1 mmol/l.
At the same time, EDEG recommends a review of the
utility of categorical labels for non-diabetic hyperglycae-
mia. It may be timely to define risk in terms of glucose as a
continuous variable. EDEG further recommends a system-
atic study of the importance and relevance of IFG to
clinical end-points through well-planned research studies.
These should include intervention trials of lifestyle and
drug interventions in adults with non-diabetic hypergly-
caemia in the primary prevention of diabetes. We also
recommend that current and future trials should focus on
CVD outcomes as well as progression to diabetes.
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